Recombinant Mouse IL-23R protein (His Tag)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg0808



Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Mouse IL-23R protein Gly24-Gly374 (Accession# Q8K4B4) with a His tag at the C-terminus.
GeneID 209590
Accession Q8K4B4
PredictedSize 41.5 kDa
SDS-PAGE 50-80 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Interleukin-23 receptor (IL23R) is a type I cytokine receptor that plays a pivotal role in the immune system, particularly in the maturation and function of T helper 17 (Th17) cells. IL23R, along with IL12Rβ1, forms the receptor complex necessary for IL-23 signaling, which is critical for the production of IL-17 and the activation of pro-inflammatory activities. This receptor is expressed on various immune cells, including T cells, NK cells, dendritic cells, and macrophages. Research has shown that variations in the IL-23R gene can significantly influence susceptibility to several diseases, particularly inflammatory bowel diseases such as ulcerative colitis (UC) and Crohn's disease (CD). In addition to UC, IL-23R has been implicated in other inflammatory conditions, including rheumatoid arthritis and ankylosing spondylitis.

References:

1.Mezghiche I, et al. (2024)Eur J Immunol. 54 (1):e2250348. 2.Peng LL, et al.(2017) Oncotarget. 8 (3):4849-4863. 3.Hamdy G, et al. (2015). Hum Immunol. 76 (6):417-20.